EI

266.6

+0.91%↑

SAN

79.56

-1.34%↓

MRK1

107

+0.23%↑

SHL.DE

47.85

+0.29%↑

ARGX

637.8

-1.24%↓

EI

266.6

+0.91%↑

SAN

79.56

-1.34%↓

MRK1

107

+0.23%↑

SHL.DE

47.85

+0.29%↑

ARGX

637.8

-1.24%↓

EI

266.6

+0.91%↑

SAN

79.56

-1.34%↓

MRK1

107

+0.23%↑

SHL.DE

47.85

+0.29%↑

ARGX

637.8

-1.24%↓

EI

266.6

+0.91%↑

SAN

79.56

-1.34%↓

MRK1

107

+0.23%↑

SHL.DE

47.85

+0.29%↑

ARGX

637.8

-1.24%↓

EI

266.6

+0.91%↑

SAN

79.56

-1.34%↓

MRK1

107

+0.23%↑

SHL.DE

47.85

+0.29%↑

ARGX

637.8

-1.24%↓

Search

Laboratorios Farmaceuticos Rovi SA

Deschisă

SectorSănătate

59.55 0.25

Rezumat

Modificarea prețului

24h

Curent

Minim

59.45

Maxim

60.7

Indicatori cheie

By Trading Economics

Venit

3.9M

27M

Vânzări

4.8M

160M

P/E

Medie Sector

23.07

35.664

EPS

0.423

Randament dividend

1.56

Marjă de profit

16.767

Angajați

2,188

EBITDA

4.2M

35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+33.53% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.56%

3.12%

Următoarele câștiguri

6 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

235M

3.1B

Deschiderea anterioară

59.3

Închiderea anterioară

59.55

Sentimentul știrilor

By Acuity

56%

44%

327 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 sept. 2025, 22:39 UTC

Achiziții, Fuziuni, Preluări

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept. 2025, 16:43 UTC

Principalele dinamici ale pieței

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept. 2025, 16:42 UTC

Principalele dinamici ale pieței

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept. 2025, 16:35 UTC

Principalele dinamici ale pieței

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept. 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept. 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept. 2025, 22:12 UTC

Achiziții, Fuziuni, Preluări

CSL Expects Commercial Launch in 2029

15 sept. 2025, 22:12 UTC

Achiziții, Fuziuni, Preluări

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept. 2025, 22:11 UTC

Achiziții, Fuziuni, Preluări

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept. 2025, 22:11 UTC

Achiziții, Fuziuni, Preluări

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept. 2025, 22:10 UTC

Achiziții, Fuziuni, Preluări

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept. 2025, 21:16 UTC

Achiziții, Fuziuni, Preluări

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept. 2025, 21:16 UTC

Achiziții, Fuziuni, Preluări

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept. 2025, 21:15 UTC

Achiziții, Fuziuni, Preluări

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept. 2025, 21:14 UTC

Achiziții, Fuziuni, Preluări

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 sept. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept. 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept. 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 sept. 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept. 2025, 17:50 UTC

Achiziții, Fuziuni, Preluări

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept. 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 sept. 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept. 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 sept. 2025, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

33.53% sus

Prognoză pe 12 luni

Medie 80.85 EUR  33.53%

Maxim 90 EUR

Minim 71.7 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

327 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat